Try
Summit Therapeutics Inc.
SMMTUnited States
40 filed reports · 652 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
40 reports · Jan 2018 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 337 interim figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 18 | 2,512 | Sep 2020 to Jun 2026 |
| Interim · 6-KSEC EDGAR | 7 | 1,221 | Apr 2018 to Mar 2020 |
| Current · 8-KSEC EDGAR | 6 | 8 | Sep 2024 to Dec 2025 |
| Annual · 10-KSEC EDGAR | 5 | 2,035 | Dec 2020 to Dec 2025 |
| Annual · 20-FSEC EDGAR | 3 | 1,200 | Jan 2018 to Dec 2019 |
| Annual · 10-K/ASEC EDGAR | 1 | 339 | Dec 2021 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 23, 2026 | 257 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 30, 2026 | 143 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 23, 2026 | 661 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 23, 2026 | 2 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 20, 2025 | 2 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 20, 2025 | 177 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 11, 2025 | 104 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 11, 2025 | 1 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | May 1, 2025 | 1 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 1, 2025 | 103 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 24, 2025 | 426 | Open |
| FY2024 Q4 | 8-K | Dec 31, 2024 | Feb 24, 2025 | 1 | Open |
Financial data
652 concepts · 7,315 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial629 concepts · 7,046 facts · Jan 2016 to Jul 2026
- Research and development tax credit receivable59 · Dec 2020 to Dec 2024
- Revenue56 · Jan 2016 to Dec 2024
- Cash cash equivalents restricted cash and restricted cash equivalents39 · Jan 2018 to Jun 2026
- Stockholders equity (US GAAP)39 · Jan 2018 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value34 · Jan 2019 to Jun 2026
- Allocated share based compensation expense34 · Jan 2019 to Jun 2026
- Common stock shares authorized34 · Dec 2019 to Jun 2026
- Comprehensive income net of tax34 · Jan 2019 to Jun 2026
- General and administrative expense (US GAAP)34 · Jan 2019 to Jun 2026
- Goodwill (US GAAP)34 · Jan 2019 to Jun 2026
- Net income loss34 · Jan 2019 to Jun 2026
- Operating expenses (US GAAP)34 · Jan 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect33 · Jan 2019 to Jun 2026
- Common stock shares outstanding33 · Dec 2019 to Jun 2026
- Depreciation33 · Jan 2019 to Jun 2026
- Foreign currency transaction gain loss unrealized33 · Jan 2019 to Jun 2026
- Increase decrease in accounts payable33 · Jan 2019 to Jun 2026
- Increase decrease in accrued liabilities33 · Jan 2019 to Jun 2026
- Net cash provided by used in financing activities33 · Jan 2019 to Jun 2026
- Net cash provided by used in investing activities33 · Jan 2019 to Jun 2026
- Net cash provided by used in operating activities33 · Jan 2019 to Jun 2026
- Nonoperating income expense33 · Jan 2019 to Jun 2026
- Payments to acquire property plant and equipment33 · Jan 2019 to Jun 2026
- Share based compensation33 · Jan 2019 to Jun 2026
Segment13 concepts · 131 facts · Dec 2022 to Jun 2026
- Allocated share based compensation expense14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Nonoperating income expense14 · Dec 2022 to Jun 2026
- Operating expenses (US GAAP)14 · Dec 2022 to Jun 2026
- Reportable Segment14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
- Interest expense nonoperating12 · Dec 2022 to Dec 2025
- Research and development expense excluding acquired in process cost12 · Dec 2022 to Dec 2025
- Acquired in-process research and development expense10 · Dec 2022 to Dec 2025
- Research and development expense4 · Mar 2025 to Jun 2026
- Operating income loss3 · Dec 2022 to Dec 2024
- Other operating income expense net3 · Dec 2022 to Dec 2024
- Revenue3 · Dec 2022 to Dec 2024
Product3 concepts · 65 facts · Jan 2017 to Sep 2023
- Revenue62 · Jan 2017 to Sep 2023
- Revenue not from contract with customer2 · Sep 2019 to Sep 2020
- Revenue (excluding assessed tax)1 · Dec 2019
Geography6 concepts · 61 facts · Jan 2016 to Dec 2025
- Revenue47 · Jan 2016 to Sep 2023
- Right of use asset obtained in exchange for operating lease liability7 · Dec 2021 to Dec 2025
- Menlo Park, California, U.S. and Sawston, UK2 · Dec 2021
- Operating lease right of use asset amortization expense2 · Mar 2024 to Jun 2024
- Revenue (excluding assessed tax)2 · Dec 2019
- Revenue from contracts with customers1 · Jan 2018
KPI1 concepts · 12 facts · Sep 2024 to Jun 2026
- Clinical Trial Participants12 · Sep 2024 to Jun 2026
Segments
257 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 131 facts
- Reportable131 · Dec 2022 to Jun 2026
Statement geographical11 members · 41 facts
- Latin America20 · Jan 2019 to Sep 2023
- US6 · Jan 2019 to Dec 2021
- Oxfordshire UK3 · Dec 2021 to Dec 2022
- CA2 · Mar 2024 to Jun 2024
- Europe2 · Jan 2019 to Dec 2020
- FL2 · Mar 2024 to Dec 2024
- Menlo Park California US And Sawston UK2 · Dec 2021
- Us1 · Dec 2019
- Menlo Park California US1 · Dec 2022
- New Jersey And California1 · Dec 2025
- Latin america1 · Dec 2019
Products and services4 members · 40 facts
- Licensingagreements14 · Jan 2017 to Mar 2020
- Researchcollaborationagreement12 · Jan 2017 to Oct 2019
- Licensingagreements11 · Oct 2017 to Mar 2020
- Researchcollaborationagreement3 · Apr 2018 to Dec 2019
Product or service4 members · 25 facts
- License And Service20 · Jan 2019 to Sep 2023
- Grant2 · Sep 2019 to Sep 2020
- Research Collaboration Agreements2 · Jan 2019 to Dec 2020
- License and service1 · Dec 2019
Geographical areas8 members · 20 facts
- US5 · Jan 2016 to Jan 2019
- Europe14 · Jan 2016 to Jan 2019
- Latin America14 · Jan 2016 to Jan 2019
- Europe2 · Jan 2018 to Jan 2019
- Latin America2 · Jan 2018 to Jan 2019
- Us1 · Dec 2019
- Europe1 · Dec 2019
- Latin america1 · Dec 2019
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary147 claims from 10 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary173 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes18 claims from 1 reports · Dec 2025
- Risk factors141 risks from 2 annual reports · 2024 to 2025
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.